Analysis of haematopoietic chimaerism by quantitative real-time polymerase chain reaction

被引:11
作者
Harries, LW
Wickham, CL
Evans, JC
Rule, SA
Joyner, MV
Ellard, S
机构
[1] Royal Devon & Exeter NHS Fdn Trust, Dept Mol Genet, Exeter EX2 5DW, Devon, England
[2] Peninsula Med Sch, Inst Biomed & Clin Sci, Exeter, Devon, England
[3] Derriford Hosp NHS Healthcare Trust, Dept Haematol, Plymouth, Devon, England
[4] Royal Devon & Exeter NHS Fdn Trust, Dept Haematol, Exeter, Devon, England
关键词
TaqMan (TM); chimaerism; SNP; real-time PCR;
D O I
10.1038/sj.bmt.1704764
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
Allogeneic bone marrow transplantation (BMT) with marrow ablative conditioning is the treatment of choice for haematopoietic malignancies. The use of nonmyeloablative stem cell transplants has allowed the treatment of patients previously ineligible for BMT because of age or other disease. These reduced conditioning regimes allow the persistence initially of some recipient cells in the blood and bone marrow ( haematopoietic chimaerism). Monitoring of the relative proportion of donor and recipient cells is required to assess the success of the procedure, to predict subsequent rejection or impending relapse and to guide the use of donor lymphocyte infusions. We present a quantitative real-time PCR approach for the measurement of haematopoietic chimaerism using the TaqMan(TM). This approach exploits the presence of single-nucleotide polymorphisms ( SNPs) to distinguish cells of patient or donor origin. We have designed and validated a panel of seven allele-specific probes to quantify the contribution of patient and donor cells in the haematopoietic population from 12 patient and donor pairs. We have compared the performance of this approach with an existing method and proved it to be superior in both accuracy and sensitivity. The use of more sensitive and accurate techniques permits earlier intervention for improved clinical outcome.
引用
收藏
页码:283 / 290
页数:8
相关论文
共 32 条
[21]  
Maas F, 2003, LEUKEMIA, V17, P630, DOI 10.1038/sj.leu.2402857
[22]  
MACKINNON S, 1994, BLOOD, V83, P3409
[23]   Mixed chimaerism is common at the time of acute graft-versus-host disease and disease response in patients receiving non-myeloablative conditioning and allogeneic stem cell transplantation [J].
Mattsson, J ;
Uzunel, M ;
Brune, M ;
Hentschke, P ;
Barkholt, L ;
Stierner, U ;
Aschan, J ;
Ringdén, O .
BRITISH JOURNAL OF HAEMATOLOGY, 2001, 115 (04) :935-944
[24]  
NAKAO S, 1992, BONE MARROW TRANSPL, V9, P107
[25]   Use of single nucleotide polymorphisms (SNP) and real-time polymerase chain reaction for bone marrow engraftment analysis [J].
Oliver, DH ;
Thompson, RE ;
Griffin, CA ;
Eshleman, JR .
JOURNAL OF MOLECULAR DIAGNOSTICS, 2000, 2 (04) :202-208
[26]   QUANTITATIVE-DETERMINATION OF BONE-MARROW TRANSPLANT ENGRAFTMENT USING FLUORESCENT POLYMERASE CHAIN-REACTION PRIMERS FOR HUMAN IDENTITY MARKERS [J].
SCHARF, SJ ;
SMITH, AG ;
HANSEN, JA ;
MCFARLAND, C ;
ERLICH, HA .
BLOOD, 1995, 85 (07) :1954-1963
[27]   Increasing mixed haematopoietic chimaerism after BMT with total depletion of CD4+ and partial depletion of CD8+ lymphocytes is associated with a higher incidence of relapse [J].
Serrano, J ;
Román, J ;
Herrera, C ;
Castillejo, JA ;
Navarro, JA ;
Reina, ML ;
González, MG ;
Rodriguez, MC ;
Pascual, A ;
Sánchez, J ;
Torres, A .
BONE MARROW TRANSPLANTATION, 1999, 23 (05) :475-482
[28]   dbSNP: the NCBI database of genetic variation [J].
Sherry, ST ;
Ward, MH ;
Kholodov, M ;
Baker, J ;
Phan, L ;
Smigielski, EM ;
Sirotkin, K .
NUCLEIC ACIDS RESEARCH, 2001, 29 (01) :308-311
[29]   Influence of CD34 cell selection on the incidence of mixed chimaerism and minimal residual disease after allogeneic unrelated donor transplantation [J].
Socié, G ;
Cayuela, JM ;
Raynal, B ;
Esperou, H ;
Fund, X ;
Raffoux, C ;
Devergie, A ;
Ribaud, P ;
Marolleau, JP ;
Parquet, N ;
Sigaux, F ;
Brison, O ;
Gluckman, E .
LEUKEMIA, 1998, 12 (09) :1440-1446
[30]  
Thiede Christian, 2004, Am J Pharmacogenomics, V4, P177, DOI 10.2165/00129785-200404030-00005